Short Interest in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Declines By 9.6%

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) TSE: AUP was the recipient of a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 6,220,000 shares, a decrease of 9.6% from the November 15th total of 6,880,000 shares. Based on an average daily trading volume, of 1,260,000 shares, the days-to-cover ratio is currently 4.9 days.

Insider Buying and Selling at Aurinia Pharmaceuticals

In related news, Director Jeffrey Allen Bailey sold 4,557 shares of the firm's stock in a transaction on Monday, November 11th. The stock was sold at an average price of $8.43, for a total transaction of $38,415.51. Following the sale, the director now owns 13,356 shares of the company's stock, valued at approximately $112,591.08. This trade represents a 25.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 4.30% of the company's stock.

Institutional Trading of Aurinia Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in Aurinia Pharmaceuticals by 1.4% during the first quarter. Vanguard Group Inc. now owns 1,531,617 shares of the biotechnology company's stock worth $7,673,000 after acquiring an additional 21,119 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Aurinia Pharmaceuticals by 15.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 38,952 shares of the biotechnology company's stock worth $196,000 after purchasing an additional 5,079 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Aurinia Pharmaceuticals by 18.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 488,721 shares of the biotechnology company's stock valued at $2,791,000 after buying an additional 77,510 shares during the last quarter. HighMark Wealth Management LLC boosted its holdings in shares of Aurinia Pharmaceuticals by 21.3% in the 2nd quarter. HighMark Wealth Management LLC now owns 91,196 shares of the biotechnology company's stock valued at $521,000 after buying an additional 16,000 shares during the last quarter. Finally, Banque Cantonale Vaudoise grew its stake in shares of Aurinia Pharmaceuticals by 126.6% in the second quarter. Banque Cantonale Vaudoise now owns 9,684 shares of the biotechnology company's stock valued at $55,000 after buying an additional 5,410 shares in the last quarter. Institutional investors own 36.83% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. StockNews.com lowered Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Friday. Cantor Fitzgerald restated an "overweight" rating and set a $10.00 target price on shares of Aurinia Pharmaceuticals in a report on Monday, September 16th. Finally, HC Wainwright reiterated a "buy" rating and issued a $13.00 price target on shares of Aurinia Pharmaceuticals in a report on Friday, September 6th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $10.00.

Aurinia Pharmaceuticals Stock Down 3.3 %

NASDAQ AUPH traded down $0.32 during trading on Friday, hitting $9.37. The stock had a trading volume of 1,279,743 shares, compared to its average volume of 1,607,037. Aurinia Pharmaceuticals has a 12 month low of $4.71 and a 12 month high of $10.67. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. The company's 50-day moving average price is $8.03 and its two-hundred day moving average price is $6.75. The company has a market capitalization of $1.34 billion, a PE ratio of -62.46 and a beta of 1.41.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.